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1. Introduction: 
 
1.1. Background: 
 
The prognosis and survival rate of a patient with non-small cell lung 
cancer (NSCLC) depends mainly upon the tumor stage at the time of 
diagnosis. In spite of significant advancement in operative techniques, 
intensive-care medicine, oncology and pulmonary medicine in the last 
thirty years, the prognosis of lung cancer has remained virtually 
unchanged (53). Ries et al in 1983 and the American Cancer Society in 
1986 pointed out that the five-year survival rate for all patients with 
diagnosed lung cancer is lower than 15% (67, 5). Even if we only 
consider the most promising stage (Ι A) for surgical resection (15% of all 
first diagnosed lung cancer), five-year survival rate of not more than 61% 
could be achieved (56).  
 
On the other hand, over 90% of patients with early lung cancer 
(carcinoma-in-situ or micro-invasive cancer) can be cured by surgery or 
photodynamic therapy (22, 33). In this radiologically occult stage, the 
diagnosis can be established by sputum cytology , (10, 18, 72) which is a 
non-invasive technique. (11) 
 
The Automated Image Cytometry (AIC) for quantitative 
measurement of DNA content and structure of exfoliated respiratory tract 
cell nuclei is considered one of the most sensitive tools developed in the 
last few years. AIC of bronchial wash in suspected lung cancer patients 
had successfully detected malignant changes with a sensitivity of 90% 
and a specificity of 84% (54). Being automated, AIC lends itself to large-
scale screening for detection of occult lung cancer. 
 
Effective treatment for a centrally located Early Lung Cancer 
(ELC) lesion can only be implemented by localization of the lesion itself. 
Localization will be improved by involvement of new technologies as 
Autofluorescence bronchoscopy (AF). Tissue autofluorescence was found 
to differentiate normal mucosa from dysplastic or carcinomatous 
bronchial mucosa without the need of exogenous sensitizers (47). Early 
results proved the superiority of combined White Light Bronchoscopy 
(WLB)/ Autofluorescence bronchoscopy (AF) in comparison to WLB 
alone with a sensitivity of 86,4% to 31,8% respectively in localizing 
moderate dysplasia and worse lesions, yielding a relative sensitivity of 
2,7 (42). 
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1.2. Cytopathological changes of early lung 
cancer 
 
In an attempt to improve the poor survival rates of lung cancer, 
therapeutic strategies require a deeper understanding of the formation and 
progression of the disease i.e. studying the different stages of 
oncogenesis.  
 
1.2.1. Definition of early lung cancer:  
 
Infiltrating growth of tumor is limited to the different layers of the 
bronchial wall, which means the tumor tissue does not exceed the outer 
tunica fibrocartilaginea, adjacent lung tissue is not infiltrated. According 
to the definition, an invasion of lymph vessels, pleura and lymph nodes 
must be excluded (17) (Fig. 1).  
 
 
 
 
 
 
 
Fig.1. Bronchial early cancer (58) 
 
 
Microinvasive carcinoma: is described as a few millimeters of basement 
membrane invasion but not involving the muscle or cartilage.  
 
Definition of Carcinoma in Situ (CIS): This includes malignant cellular 
changes in the full thickness of the mucosa but an intact basement 
membrane (21). CIS is usually squamous cell carcinoma.  
 
1.2.2. Endoscopic appearance of early lung cancer: 
 
In 1994, Akaogi and Coworkers studied the relationship between 
endoscopic criteria of 44 resected, roentgenographically occult, early LC 
lesions and the degree of histologic extent of the tumor. According to the 
endoscopic and macroscopic findings, the lesions were devided into three 
types (3): 
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1- Polypoid or nodular (PN): The PN type was a polypoid or a well 
defined nodular lesion locally protruding from the surface of the 
bronchus (Fig. 2 A.) 
2- Flat spreading (FS): The FS type had a non polypoid, but usually a 
rather thickened appearance of the bronchial mucosa with a slightly 
rough surface, chiefly resulting in thickening of the bronchial spur. 
Also, It is characterized by paleness, redness, microgranularity or loss 
of luster in the surface mucosa (Fig. 2 B.). 
3- Mixed Type: The mixed type was a protruding nodule surrounded or 
accoumpanied by an irrigular thickening of the bronchial surface.     
 
It was showen that FS type is the most common growth pattern in the 
central bronchus (19/33) and the only one peripherally (11/11). 
 
Fig. 2.A. Scheme of Polypoid type  Fig.2 B.Scheme of Flatty Spreding 
of early LC (58)                       type of early LC (58) 
 
 
PN and mixed types were found of the same proportions (7/33 each) and 
only centrally.  
   
  Lesion type and size were correlated to the depth of bronchial 
invasion and LN envolvement. So, endoscopic criteria of small 
endobronchial lesions could disclose information on the stage of the 
disease. Central PN lesions smaller than 10 mm and central FS lesions 
less than 15mm in greatest dimension were likely to be early lung cancer. 
 
1.2.3. Outcome of Preneoplasia: 
 
There is good evidence to indicate that the natural history of lung cancer 
in these very early stages may extend over a period of years before the 
tumor becomes radiographically demonstrable. However, the extent to 
which preneoplastic lesions precede one another in time and their precise 
outcome remains largely unknown (83). On the basis of cytological data, 
studies showed that approximately 11% of moderate dysplasia and 19% 
to 46% of severe dysplasia would progress to invasive cancer. (8, 68). 
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Also, Saccomanno et al. in 1974 recorded the average times of transition 
from carcinoma in situ to invasive squamous cell carcinoma at 2.5 years, 
ranging from 0.6 - 6.2 years (71). Meanwhile, many authors reported the 
regression of some preneoplasias and even CIS after withdrawal of the 
carcinogenic insult-usually cigarette smoking (75). Finally, and in a 
recent study conducted by Venmans et. al in 2000, they followed up their 
diagnosed cases of CIS and described that 78% of these lesions 
progressed into invasive cancer recommending the mandatory treatment 
of these lesions (81).   
 
1.3. Importance of endoscopic early lung cancer detection: 
 
Experienced bronchoscopists can detect 29% of carcinomata-in-situ and 
60% of micro-invasive carcinoma (Woolner 1983). A more sensitive 
method for detection and localization of early lung cancer is needed 
urgently as well established methods for early treatment of CIS and 
micro-invasive cancer (19, 28) are available even for functionally 
inoperable patients. ND-YAG Laser, electrocautery, photodynamic 
therapy and cryotherapy are all useful tools for such a therapy. 
  
Meanwhile, a clear relation between the surface area of the lesion 
and the success of treatment was observed by Hayata et al in 1993. A 
lesion < 1cm will be eradicated by photodynamic therapy in 97.8%, while 
in lesions > 1cm, cure will be achieved in only 42.9% (33). So, the early 
diagnosis directly influences the success of treatment. As improvements 
in image resolution and quality have not enhanced detection of early lung 
cancer, technical developments turned to getting help from other optical 
qualities e.g. the native fluorescence characteristics of the endobronchial 
epithelium. 
 
1.4. The screening problem: 
 
Two screening methods were applied trying to improve the early 
diagnosis and respectively the prognosis of lung cancer, plain chest x-ray 
and sputum cytology. Sputum is collected for three days in a special 
conserving solution, a technique suggested by Saccomanno for a better 
diagnosis rate of lung cancer. Material subsequently stained according to 
papanicolaou stain and microscopically examined. These methods were 
tried in large studies (30, 55). Study end point was lung cancer mortality 
reduction. The Mayo clinic lung project (4 monthly chest x-ray and 
sputum cytology in the test group versus once yearly clinical examination 
in the control group) recruited 9211 male smoker in their project. 
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Although they could improve the percentage of resectable lung cancer 
cases from 32% of the diagnosed cases to 46%, the difference in 
mortality rate between the examined group and the control group 
remained unchanged. Similarly the Memorial Sloan-Kettering and the 
Johns Hopkins projects (once yearly chest x-ray in both groups plus 4 
monthly sputum cytology in the first group only) showed no change in 
mortality rate.  
 
The conclusion from the above-mentioned data was that screening 
sputum cytology did not decrease the mortality rate. The overall 
sensitivity of sputum cytology was 22% and 48.7% (30). Early lesions of 
non-small cell lung cancer in John Hopkins study were sputum positive in 
15% only. A lot of peripheral lesions were not represented in sputum. The 
specificity of sputum cytology is high (26). From 81 cases with stage I 
tumor in the Mayo clinic lung project, 44 cases were x-ray positive 
(peripheral adenocarcinoma), 30 cases were sputum cytology positive and 
radiologically occult (central squamous cell carcinoma), and 7 cases were 
radiologically evident and sputum positive. Sputum cytology and chest x-
rays complement each other in detecting early lung cancer.  
 
To summarize, it was found that the value of chest x-ray in 
screening is debatable, no added advantage for using sputum cytology 
could be proved and both methods did not effectively reduce the 
mortality rate. Screening for lung cancer was abandoned as a waste of 
resources (4, 27). 
 
1.5. Automated Image Cytometry (AIC) 
 
1.5.1. Background: 
 
DNA cytometry has gained wide acceptance in pathology and 
cytopathology as a means to obtain objective information concerning the 
diagnosis and grading of human cancer (12). With this technique, cells 
are stained specifically for DNA, and digital images of microscope fields 
are acquired, typically using a CCD camera. Computers are used to 
process the digital images and to perform a wide variety of Nuclear 
feature measurements, such as the size, shape, and DNA content, as well 
as features describing the spatial distribution of chromatin within the 
nucleus (24). 
 
One of the most widely applied image cytometry measurements is 
that of DNA content of the nucleus which is accepted by an international 
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consensus group (1). Using this new technique, we can detect not only the 
DNA amount inside the nucleus but also the chromatin structure and 
distribution. As a rule, the higher the malignancy grade of the tumor, the 
higher will be the DNA content, its uneven distribution and the number of 
aneuploid cell nuclei. The genetic basis for the relevance of tumor 
aneuploidy measurements has been well established through cytogenetic 
studies of tumor cell populations (29). In these studies, correlation was 
demonstrated between cytometric measurements of aneuploidy and gene 
or chromosome amplification processes. In addition, karyotypic 
instability has been shown to have dramatic effects on DNA content 
distribution in tumor cell populations. 
 
However, the DNA content of exfoliated cells from the respiratory 
tract can be affected by a number of factors that must be considered in the 
differential diagnosis of either sputum cytology or cytometry. Some of 
these are the replication rate, (polyploidal) nuclei, nonspecific effects of 
chemotherapy and radiotherapy, vitamin B12 deficiency, autolysis, 
necrosis and viral infection. 
 
 The Cyto-Savant® is a promising device developed recently in 
corporation between the British Columbia Cancer Agency and 
Oncometrics Corp. Vancouver BC, especially for gynecological 
screening examinations (31) Fig 3. 
 
1.5.2. Method of Automated Image Cytometry:  
 
The prerequisites of AIC was determined in the consensus report of the 
European society for analytical cellular pathology task force on 
standardization of diagnostic DNA image cytometry (12). An automated 
cytometer device requires a high resolution level by provided efficient 
focus range. DNA content and structure of a nucleus must be measured 
independently from a monolayer slide without any qualitative or 
quantitative failure.  
 
The device (Cyto-Savant®) feeds the microscope automatically 
with slides. Nuclei are focused by a high spatial and photometric 
resolution. For every object, the program will calculate 114 features that 
will identify and eliminate artifacts and then will classify cells into 
groups of lymphocytes, granulocytes, epithelial nuclei, alveolar 
macrophages and abnormal or suspicious nuclei. 
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Fig. 3. Photo of Cyto-Savant® (from right to left: automatic slide 
              supplier, Microscope with a connected CCD camera, monitor 
              for microscope, magnetic disk operator and the analysis monitor) 
 
A representative number of leucocytes will be taken to normalize 
the features as regards to the different staining characteristics between 
different batches of slides. Then with the use of trainable classifiers, will 
the different nuclei be arranged in different groups and their picture will 
be projected on a screen. From every group, the mean and standard 
deviation of every feature will be calculated and tabulated. Then a 
distribution histogram of different feature combinations will be obtained. 
 
1.5.3. Technical specifications: 
 
A special CCD (charge couple device) camera is used. It observes 
the whole field at the same time with a picture frequency of 20 MHz 
without blind spots. (Fig. 4) is an example for such a camera 
(Microimager 1400), Xillix Technologies Corporation.  
 
1.5.4. Cell tracking: 
 
In the current version, the cytometer identifies and analyses up to 50.000 
objects in 30 minutes. About 2000 cells (1000 epithelial cells, 200 
suspicious nuclei with a DNA index of more than 1.25 and less than 2.5 
and up to 100 highly suspicious ones with a DNA index of more than 2.5) 
were collected and stored. Along with the epithelial cells, up to 200 
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lymphocytes, polymorphonuclear and eosinophil granulocytes were 
identified and 100 alveolar macrophages each. 
 
 
Typical sensor of a video camera  Special CCD sensor 
 
Fig.4. Difference between CCD sensors and conventional video cameras:  
           normal video image has blind spots, CCD has the full-fill factor,  
           i.e., no blind spots. 
 
The standard value for the integrated optical density (IOD) of epithelial 
cells was 110. For each of the 2000 cells, digital values of all features 
were calculated and stored. Coordinates of all cells were stored and 
suspicious cells could be revisited interactively. The DNA amount of 
normal epithelial nuclei, referred to as 2c value or euploidy value, is 
calculated from a representative group of lymphocytes.  
 
Three parameters were calculated from the DNA value of epithelial 
nuclei: the rate of 5c exceeding nuclei (5cER), the 2c-deviation index 
(2cDI) and the malignancy grade (MG). The 5cER is the rate (in %) of 
aneuploid nuclei with a DNA amount > 5c. These are different from 
normal separating mitotic nuclei. Nuclei are called euploid if their DNA 
amount is in the range 2c ± 0.25c. 2cDI is defined as the sum of all 
squared deviations of the DNA amount of all epithelial cells (Ci) from the 
mean value (2c) divided by the number of cells. This value is equivalent 
to the mean square from the deviation of the mean diploid value. Further 
gradations are based on the malignancy grade (MG) as the 
logarithmically transformed 2cDI. This procedure allows quantifying the 
whole spectrum of malignancy with the help of a simple score.  
 
 
 
 
Active
Blind
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1.6. Autofluorescence Bronchoscopy (AF) 
 
1.6.1. Historical background:  
 
The concept of fluorescence detection, as an aid for diagnosis of 
malignancies, has intrigued the minds of many since the beginning of the 
twentieth century. Policard observed red fluorescence under ultraviolet 
light as early as 1924 in an experimental model of mouse sarcoma (65). 
The trial of intra-operative differentiation between normal and tumor 
tissue with the help of an ultraviolet operation lamp was an early 
application of this concept. Subsequent investigations showed that this 
red fluorescence was due to the presence of porphyrins.  
 
In 1933, Sutro and Burman observed that when surgically excised 
breast tissue was exposed to ultraviolet Woods light, normal breast tissue 
fluoresced green while breast cancer tissue fluoresced purple and this 
could be helpful in detecting resection borders (74). It was also observed 
by Ronchese in 1954 that advanced cancer of the breast, mouth or skin 
emits a bright red fluorescence upon illumination by Woods light (69). 
  
In 1964, Lipson at Mayo clinic synthesized hematoporphyrin 
derivative (HpD) (52). HpD was found to have superior tumor localizing 
properties than hematoporphyrin alone for a variety of tumors including 
lung cancer. The partially purified preparation is known as photofrin 
(profimer sodium). Although various experimental fluorescence 
bronchoscopy systems have been developed to localize early lung cancer 
as well as to treat invasive tumors by using HpD or photofrin (20, 40), 
clinical application has been limited by several problems:  
 
a) The fluorescence yield from a small, thin CIS is often weak when 
compared to invasive cancers. 
b) Some areas with diffuse fluorescence and blurred margins or areas 
with low contrast are difficult to differentiate from the normal 
background.  The magnitude of this contrast appears to correlate with 
the stage of cancer, with the more invasive tumors showing the 
highest contrast. (15). 
c) Baumgartner in 1991 proved the non-specific uptake of the 
fluorescent drug by inflammatory cells. He showed 27% false positive 
results even with a dose of photofrin that is one-fifth of that 
conventionally used for photodynamic therapy (9). 
d) The serious side effects of photofrin or HpD as regards skin 
photosensitivity. Patients who have received photofrin or HpD have to 
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remain out of any strong light for thirty days and sometimes for 
several months (25). 
e) Almost all of the fluorescent drugs are available for investigational 
use only. Even when these drugs become available for clinical use, 
they will add to the cost of bronchoscopic examination (51). 
 
An interesting finding was the discovery that detection of dysplasia 
and carcinoma in-situ by fluorescence techniques can be achieved 
without using any drug at all. In vivo spectroscopy during bronchoscopic 
examination with an optical multichannel analyzer and a Helium - 
Cadmium Laser (442 nm) for illumination showed a significant decrease 
in autofluorescence intensity, predominantly in the green region of the 
visible spectrum in areas with dysplasia or CIS compared to normal 
bronchial tissue (35). The advancement in technology of screen resolution 
and computer data analysis in the last few years helped the development 
of this discovery (66). A well established, now in routine use, system was 
developed in association with the British Columbia Cancer Agency, the 
LIFE-Lung  (Laser Induced Fluorescence Emission) system (Xillix)®  
Fig. 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Photo of Xillix LIFE-Lung Fluorescence Endoscopy System®  
              (right: Imaging console integrating the CCD camera with 
              suspension system, touch screen monitor, processor and a VCR.  
              Left: Illumination console for He-Cd laser) 
 
 
 
 
_____________________________________________________________________Introduction 11
1.6.2. Causes of autofluorescence phenomenon: 
 
Fluorescence is a physical phenomenon, which appears when atoms in 
tissues are excited with light photons of a specific wavelength that are 
absorbed by electrons causing their movement to a higher energy level. 
The electron gives up its energy after a short time and returns to its 
original orbital emitting its energy as photons. This emitted light is the 
source of fluorescence, which is taken up and processed by the highly 
sensitive CCD camera (fig 6). 
 
 
 
 
 
 
 
 
 
 
 
  
(a) Absorption    (b) Fluorescence 
Fig. 6. Showing (a) absorption of photons by electrons and its movement  
            to a higher energy level (excitation) and (b) emission of this  
            energy in the form of photons giving rise to fluorescence.     
 
This reaction appears in living as well as dead tissues and it has long been 
used as a parameter to differentiate between healthy and diseased tissues. 
Tissue substances emitting fluorescence are named fluorophores and 
tissue type and metabolic state control their localization and 
concentration. The following substances found in the human body act as 
fluorophores: (Table 1)  
 
Table 1. Fluorescing Substances in human body 
Fluorescent substance wavelength of 
excitation light (nm) 
Fluorescent 
wavelength (nm) 
1- Tryptophan 280 340 
2- Collagen 325 380 
3- Elastin  410 440 
4- NADH 365 470 
5- Flavin 440 520 
6- Porphyrin 400 630,690 
Atom nucleus (+) 
Electron (-)  
Exciting light 
emitting photons 
Electron gives up 
energy emitting 
fluorescence 
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The causes of the difference in fluorescence properties is a matter of 
research till now. Difference in epithelial thickness, increased blood 
supply in malignant lesions through increased vascularisation 
(hemoglobin absorbs nearly all the green light), the over-production of 
lactic acid by cancerous cells due to increased glycolytic activity and the 
change in concentration and oxidation state of the fluorophores may all 
play a role (35, 6, 2). 
 
Non imaging instruments have been devised primarily to allow 
quantitative measurements of fluorescence or fluorescence ratios in 
different wavelength bands. Disadvantages of the non-imaging systems 
are the non-precise delineation of lesions, very small lesions can be 
missed and in vivo calibration may take by chance a reference area of 
unknown dysplasia or metaplasia (45). 
 
1.6.3. Instrumentation: 
 
1.6.3.1.The LIFE® Lung system:  
 
Fluorescence bronchoscopy requires a bronchoscope, a light source for 
excitation of fluorescence and a detection system.  
 
The bronchoscope used is a conventional white light flexible 
fiberscope. The light source for white light bronchoscopy is a xenon arc 
lamp, typically 200-1000 W. this source delivers a broad spectrum in the 
visible range; the accompanying infrared emission is filtered out. A white 
light source is probably not suitable for fluorescence bronchoscopy, 
because the nonspecific part of the spectrum overlaps the weak 
fluorescence of interest, making it impossible to detect. There are new 
mercury arc lamps that are coupled with small fiberoptic light guides and 
appropriate filters that filter out the longer wavelengths overlapping the 
fluorescence, which can replace more expensive laser light sources (51). 
 
The preferred light source is a low energy 150-mW laser, emitting 
about 12-20 mW at the distal end of the light guide bundle. At a typical 
bronchoscope-to-tumor distance of about 1cm, this power is sufficient 
and avoids thermal effects. For excitation of autofluorescence, a helium-
cadmium laser has been found suitable, emitting in the blue range at 442 
nm (35, 61, 47, 50). The blue light is transmitted through the built-in 
fiberoptic light guide normally used for white-light illumination. It is 
important that the spatial distribution of the irradiance in the bronchus is 
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quite uniform; otherwise irregular shadows caused by non-uniformity or a 
projection of tissue could be mistaken for a tumor. 
 
  The detection system for imaging is critical, and various solutions 
have been proposed. The eye alone is not sensitive enough to detect the 
weak fluorescence from small, thin tumors even when they contain a 
fluorescent agent such as photofrin, especially considering the light losses 
in the bronchoscope. Theoretically, increasing the laser power and hence 
the excitation irradiance would increase the fluorescence intensity. A 
higher output laser may damage normal tissue. Instead, image intensifiers 
are used to amplify the weak fluorescence signal to a level that can be 
detected by the light-adapted eye (necessary in the bronchoscopy 
environment) or a CCD video camera (51). 
 
LIFE is comprised of a low energy helium-cadmium laser as a 
monochrome light source (442 nm), two images intensified CCD cameras 
with green and red filters respectively, a computer with an imaging board, 
and a color video monitor. Two images at different (red and green) 
wavelengths are simultaneously captured in precise registration by the 
imaging board. When the bronchial epithelium is illuminated by the blue 
light, it will have its peak of fluorescence in the green wavelength (520 
nm). Premalignant changes as dysplasia or CIS will emit red-brown color 
with a wavelength of 630 nm as seen in fig 7 
 
The above mentioned filters capture the emitted wavelengths from 
the bronchial epithelium in the spectrum of 520 nm and > 630 nm and 
exclude the excitation wavelength (51). 
 
The images are then combined and processed by the imaging board 
using a specially developed algorithm that allows normal tissue to be 
clearly distinguished from malignant tissue when displayed as a 
pseudocolor image on the video monitor. The captured image is displayed 
in real time (at video rates). The processed image can be displayed as 
desired, for example, normal tissue as green and tumor tissue as brown or 
brownish red. An abnormal area can be biopsied under direct vision for 
pathological confirmation. 
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Fig. 7. Fluorescence light-emitting characteristics of normal 
   and dysplastic bronchial mucosa 
 
1.6.3.2. Other autofluorescence devices: 
 
Increasing interest in ELC detection has encouraged the development of 
more imaging AF-bronchoscopy systems with slightly modified 
technique. System D-Light AF (Storz, Germany), a system adapted to 
rigid bronchoscopy as well uses filtered Xenon instead of laser light for 
excitation (32). Impairment of AF can be observed either through the 
bronchoscope directly or with the help of a video camera. Prolonged 
exposure time required for the AF video camera mode leads to sequential 
frozen frames on the monitor. With the System D-Light as well as with 
the similar SAFE 1000 System (Pentax, Japan) switching between WLB 
and AF-mode is possible without changing light source and camera. The 
display of AF-images with the SAFE 1000 provides a continuous real 
time image; the system is adapted to flexible bronchoscopy (37). 
 
1.6.4. Clinical applications of AF: 
 
The LIFE imaging system facilitates earlier detection of lung cancer and 
provides physicians with more information for the management of the 
diagnosed lung cancer patients. Using the LIFE imaging system for the 
following indications will supply useful diagnostic information. 
 
Diagram of tissue autofluorescence 
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1.6.4.1. Indications of AF examination: 
 
Patients at high risk for lung cancer are the target group for AF 
examinations. These are: 
 
1- Patients with previously resected for cure lung cancer: Patients 
with previously resected stage I lung cancer have local recurrences or 
second primary lung cancers at a rate of approximately 3.6 per year 
(77). From what is known about the natural history of lung cancer 
(70), the second primary cancers that where diagnosed in the first 3-5 
years after surgery where probably present as dysplasia or CIS at the 
time of initial bronchoscopy before surgery and were missed by white 
light bronchoscopy. 
2- In preoperative assessment of patients with lung cancer: in order 
to determine the extent of endobronchial involvement and resection 
margins respectively.   
3- Patients with suspected bronchogenic carcinoma: (symptoms, 
abnormal chest x-ray, positive sputum cytology or cytometry, 
undiagnosed pleural effusion or paraneoplastic syndrome). 
4- Patients with head and neck cancers: as there is a high incidence in 
developing a second primary cancer not only locally but also in the 
lungs (62).  
5- Individuals at otherwise high risk of developing lung cancer: i.e. 
patients who are current or past heavy smokers with positive family 
history of lung cancer, workers with asbestos or other relevant 
industrial exposure. 
 
 1.6.4.2. Other potentially useful Applications: 
 
1- Delineation of the exact extent of the tumor before photodynamic 
therapy is of particular importance for dosimetry calculation, fiber 
type, total treatment sessions and to ensure complete eradication of the 
entire tumor (50). 
2- Autofluorescence bronchoscopy may serve as a vehicle to educate 
bronchoscopists in recognizing subtle changes during routine 
bronchoscopy. 
3- This method allows detection and biopsy of pre-malignant respiratory 
epithelium for genetic and differentiation marker studies. 
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1.6.4.3. Contraindications for AF examination: 
 
1- Patients with known or suspected pneumonia. 
2- Patients with acute bronchitis within one month of the procedure. 
3- Patients with white count less than 2000 or more than 20 000, and/or 
platelet count less than 50 000. 
4- Patients who had received fluorescent photosensitizing drugs such as 
photofrin within three months of the procedure. 
5- Patients who are on, or have received chemopreventive drugs (e.g. 
retinoic acid) within three months of the procedure. 
6- Patients who had received ionizing radiation treatment to the chest 
within six months of the procedure. 
7- Patients who had received cytotoxic chemotherapy agents 
systematically within six months of the procedure. 
8- Other general contraindication for bronchoscopy as patients with 
bleeding disorders, left ventricular failure, uncontrolled hypertension, 
unstable angina and known reaction to topical xylocaine. 
 
1.7. Aim of the study: 
 
The following questions will be addressed in this study: 
1- Is automated image cytometry a sensitive tool for recognizing early 
malignant changes in nuclei of bronchial mucosal cells? 
2- Is autofluorescence bronchoscopy a reliable and sensitive tool for 
early detection and localization of centrally located early lung cancer 
lesions?  
3- Can an increase in the diagnostic rate of preneoplasia be achieved by 
the combined use of automated image cytometry and white 
light/autofluorescence bronchoscopy?  
 
The study is conducted at the Research Institute for Diagnosis and 
Treatment of Early Lung Cancer (RIDTELC) of the Augusta Teaching 
Hospital in Bochum, Germany. 
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2. Patients and Methods 
 
2.1. Recruitment of patients: 
 
For this prospective case finding study, we recruited 119 high-risk 
patients from January 1999 till June 2000 in whom all initial radiological 
investigations for presenting complaints were negative for lung cancer. 
All patients submitted a sputum sample for AIC, underwent white light 
(WLB) and autofluorescence (AF) bronchoscopy with bronchial 
washings for AIC and conventional cytology (CY). Endoscopically 
suspected lesions were biopsied and examined histopathologically. A 
total of 150 examinations were performed on these patients after taking 
informed consent from each of them. 
 
2.2. Inclusion criteria:  
 
1- Patient should be able to give an informed consent. 
2- Patients are at high-risk for lung cancer. For example, they should 
have either: 
A) Heavy smokers with a positive family history of lung cancer, 
occupationally exposed workers to carcinogenic substances as 
uranium miners, COPD with a change in symptoms as recurrent 
unexplained hemoptysis. 
B) Follow up of resected for cure lung cancer to search for recurrence in 
resection margins or second primary. 
C) Previous atypical cytological or cytometrical results of bronchial 
secretions. 
D) Patients at otherwise high-risk for developing lung cancer for 
miscellaneous reasons as patients with upper digestive or respiratory 
tract cancers or head and neck cancers. 
 
2.3. Exclusion criteria: 
 
1- Definite endobronchial tumor growth.  
2- Acute bronchopulmonary infection with possible bronchial hyperemia 
and increased coughing. 
3- Radiotherapy and or chemotherapy 6 months prior to the examination. 
4- Interventional bronchoscopic procedures 2 months prior to the 
examination including biopsy as this will artificially reduce AF. 
5- Current photosensitizing medications such as photofrin. 
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6- Contraindications of WLB in general as unstable angina, bleeding 
tendency, left ventricular failure, uncontrolled hypertension and 
allergy to local anesthesia. 
 
2.4. Investigations: 
 
1- Full history and clinical examination. 
2- Chest x-rays and computed chest tomography if necessary. 
3- Sputum sample for automated image cytometry examination with 
Cyto-Savant®. 
5- White light bronchoscopy with Olympus BF 20 or 40, Tokyo, Japan). 
6- Autofluorescence bronchoscopy with LIFE® system. 
7- Bronchial washings for conventional cytology as well as automated 
image cytometry also with Cyto-Savant®. 
8- Bronchial mucosa biopsies for histopathological examination or 
brushing for cytology were done when a preneoplastic lesion was 
suspected under White Light Bronchoscopy (WLB) and/or 
Autofluorescence Bronchoscopy (AF). 
 
2.5. Sputum collection /preparation for bronchoscopy: 
 
1- After giving informed consent for the examination, an intravenous line 
was introduced and topical anesthesia was applied by inhalation of 5 
ml Lidocaine 4% solution for 10 minutes through an ultrasonic 
nebulizer. 
2- The patient was instructed to cough as deep and as strong as possible 
and to expectorate about 10-15 ml into a container with 20 ml 
Saccomanno solution (50% ethyl alcohol & polyethylenglykol) mixed 
with 0.2% dithiothreitol for good sputum liquefaction. 
3- Bronchoscopic procedure: in a recumbent position, intravenous 
sedation with midazolam was sometimes given and individually 
titrated to keep the patient calm and prevent excessive and frequent 
coughing during the examination. Such cough can traumatize the 
bronchial mucosa against the bronchoscope or cause petichial 
hemorrhages from severe Valsalva maneuver and both will reduce 
autofluorescence making it difficult to diagnose minute preneoplastic 
lesions especially for the inexperienced. The fiberoptic bronchoscope 
was coupled with a conventional video camera and introduced 
transnasally when possible, otherwise transorally under nasal oxygen 
supplementation and pulse oxymeter control. Careful bronchoscopy 
was done to prevent unnecessary mucosal trauma.  
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After documenting all suspicious lesions under WLB, the laser light 
source was connected to the fiberoptic bronchoscope and the CCD 
camera replaced the conventional video camera. Suspicious lesions under 
AF were also documented then reexamined again by WLB and 
documented if they were previously classified as non-suspicious. Then 
biopsy was taken from all suspiciously classified lesions either with one 
or both methods. Biopsies were taken separately using a new forceps for 
each lesion to prevent contamination. 
  
2.6. Documentation:   
 
The whole examination during WLB and LIFE was video documented. 
Freeze frames of all suspect lesions were stored in WLB and AF together 
with the endoscopic evaluation. AF suspicious lesions overlooked in 
WLB were captured as freeze frames but classified as non-suspicious. 
 
2.7. Chronology of specimens collection: 
 
After completion of documenting all findings, bronchial washings from 
central airways were the first specimens to be taken. Then all 
endoscopically suspicious areas with either one or both methods were 
biopsied and sent for histopathological examination. All obviously 
invasive tumors, which were radiologically occult, were biopsied for 
diagnosis but excluded from the study. If there were no suspicious 
lesions, no biopsies but bronchial washings were taken for cytology and 
automated image cytometry to search for peripheral early lung cancer 
lesions that could not be reached by the bronchoscope as well as centrally 
located lesions that may be missed from both endoscopic methods. 
 
2.8. Technique of endoscopic specimen collection:  
 
Bronchial washings were done by instilling 4 x 10ml isotonic saline on 
main carina and suctioning at least 20ml from both sides of the bronchial 
tree. 
 
The washings were equally divided into two test tubes; one 
containing 10 ml of 50% alcohol as a fixative for cytological examination 
and the other with 20 ml Saccomanno solution for automated image 
cytometry. Suspicious lesions were biopsied either with a toothed biopsy 
forceps (Olympus FB 19 C) or by brush (Cellebrity 1.7mm, 
Microvasive). Biopsied tissues were either collected in 4% formaline 
solution for staining with Hematoxilin & Eosin and with Giemsa stain for 
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histopathological examination or spread on a slide, air dried and stained 
according to Papanicolaou for cytological examination. 
 
2.9. Evaluation criteria: 
 
2.9.1. Endoscopic Image Classification: 
 
The examiner's impression for the image diagnosis of a suspicious lesion 
was classified and documented as follows: 
 
Class I: for normal bronchial mucosa or benign unsuspicious lesion as 
inflammatory changes. 
Class II for suspected preneoplastic or early carcinomatous lesion. 
Class III for definite invasive tumor growth. Class III was totally 
excluded from the analysis Fig 10. 
 
a) White light bronchoscopic image classification: 
 
Class I for normal or diffuse redness with or without edema of bronchial 
mucosa (inflammation), granuloma, angioma, scaring, telangektasia and 
trauma Fig. 8. 
Class II for localized redness or paleness with well-circumscribed edema, 
thickening of carina, loss of luster, irregular mucosal surface of small 
polyps. 
Class III for definite endobronchial tumor growth, mucosal infiltration 
with loss of normal structure, bronchial wall stiffness, vulnerability and 
bronchial stenosis Fig. 10. 
 
b) The corresponding classification in autofluorescence mode was: 
 
Class I for bright green mucosa, well-demarcated dark brown in 
hematoma, or superficial vessels. Fig 8. 
Class II for well-demarcated homogenous, dark brown area Fig 9. 
Class III for well-demarcated, dark brown color may be with areas of 
exaggerated green fluorescence (necrotic tissues or destroyed cartilage) 
Fig 10. 
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Fig. 8 Normal main carina under WLB and AF modes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.9 Severe dysplasia of Rt. upper lobe carina  
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Fig. 10 Tumor growth in Lt. Upper Lobe Bronchus 
 
2.9.2. Histopathological Classification of biopsies: 
 
The histological diagnosis of mucosal structure was done according to the 
WHO criteria 1981 (Histological typing of lung tumors). In: WHO (Ed.): 
International histological classification of tumors (1981). 
 
 
1.0 Normal 
2.0 Inflammation 
3.0 Hyperplasia 
4.0 Mild dysplasia 
5.0 Moderate - Severe dysplasia 
6.0 Carcinoma in situ (CIS)  
7.0 Microinvasive carcinoma 
8.0 Invasive carcinoma 
8.1 Squamous 
8.2 Adeno 
8.3 Large cell 
8.4 Small cell 
8.5 Other 
9.0 Unsatisfactory specimen. 
 
For final pathologic diagnosis, the nine point's scale was converted into a 
three-points. Codes 1-4 were considered negative, codes from 5-8 were 
considered positive and code 9 was labeled 'not evaluable'. 
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2.9.3. Cytological grading of Bronchial Secretions:  
 
For cytological diagnosis is a modified classification of Papanicolaou was 
applied: 
 
Pap 0:  not representative. 
Pap I:  Normal. 
Pap II:  benign diagnosis as inflammation. 
Pap III: cellular proliferation with atypia. 
Pap IIID: dysplasia (sub-classified into mild, moderate and severe). 
Pap IVa:  carcinoma in situ. 
Pap IVb: only one definite tumor cell (carcinoma highly possible). 
Pap V:  a lot of definite tumor cells (certain carcinoma). 
 
In cytological evaluation, PapI - IIIDL (from normal up to mild dysplasia) 
were considered negative and Pap IIIDM - PapV were evaluated as 
positive. 
 
2.9.4. Automated image cytometry classification: 
 
In our analysis, we used the most important two parameters, the 
2cDI along with the virtual diagnosis of morphologically abnormal 
nuclei. Following the recommendations of the ESACP for quantitative 
cytometry (12), we used the following categories (0, I, II and III) as 
shown in table (2): 
 
Table 2. Classification of Preneoplasia Stages by AIC 
Grade Meaning Description 
0 Non-representative Too few diagnostic cells from the 
airways 
I Benign Normal nuclear structures, euploidy, 
2cDeviation Index (2cDI) <0.20 
II Suspicious Samples with more than 1-2% 
suspicious nuclei, 2cDI >0.20  
III Highly suspicious 2cDI > 0.20, numerous abnormal 
nuclei, including those with a DNA 
index of more than five times (5c) the 
normal haploid DNA content (5cER> 
0.2%). 
 
The AIC evaluation was converted from 3 point scale into 2 point 
scale: 2cDI < 0.2 and objective diagnosis as non-suspicious were all 
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labeled negative and 2cDI > 0.2 and objective diagnosis as suspicious 
were considered positive. 
 
2.10. Follow up of diagnosed preneoplasias: 
 
All cases of moderate dysplasia or worse were followed up for at least 6 
months in 3 months intervals with AIC and AF. These patients were 
either treated interventionally or conservatively according to the 
following scheme: 
 
a) Cases of CIS:  
 
All CIS and worse cases were treated. The choice of treatment modality 
depended mainly upon the general condition of the patient, his pulmonary 
function reserve and the multi-centricity of the early tumor. Patients with 
depleted pulmonary reserves were treated by endobronchial ND-YAG 
laser. In the meanwhile, surgical resection of the affected segment or lobe 
was preferred in localized lesions with acceptable preoperative 
assessment.  
 
b) Cases of moderate-severe dysplasia: 
 
Cases of moderate to severe dysplasia were given steroid inhalation for 3 
months to dampen inflammation and the patient was instructed to stop 
smoking. If dysplasia persist, treatment and follow up was conducted as 
previously mentioned in CIS. Usually endobronchial intervention by ND-
YAG laser was sufficient. 
 
2.11. Methods of statistical analysis: 
 
Sensitivity and specificity of AIC and/or WLB/AF were tested against the 
histopathological and /or cytological diagnosis as the gold standard. 
Statistically unbiased estimates of sensitivity and specificity were not 
possible to obtain because serial sections of the entire tracheobronchial 
tree would need to be examined after bronchoscopic procedures for these 
to be defined. However, since the objective of the study was to determine 
whether the addition of AF to WLB was better than WLB alone, and 
whether the addition of AIC to WLB/AF examination would improve the 
sensitivity of detecting new early lung cancer, the relative sensitivity 
between WLB/AF to WLB alone was calculated along with the 95% 
confidence interval (from Ciba Geigy Scientific tables 1980) to detect the 
contribution of such relatively new technologies in detecting early lung 
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cancer. Also, the positive predictive value, negative predictive value, 
diagnostic efficiency were all calculated to evaluate the performance. 
 
The data were evaluated on a per-patient bases and not on a per 
lesion basis as the latter method has its consequences on further 
management of individual lesions and not on the rate of detecting new 
early lung cancer cases. 
 
Definition of Sensitivity: The probability of a test to be positive if the 
disease is truly present. 
 
Sensitivity = True positive/True positive + False negative 
 
Definition of Specificity: The probability of a test to be negative if the 
disease is truly absent. 
 
Specificity = True negative/ True negative +False positive  
    
Relative sensitivity  = Sensitivity of WLB+AF/ Sensitivity of WLB alone. 
A relative sensitivity more than one would indicate a real improvement in 
detection rate of WLB+AF vs that of WLB alone.  
 
Definition of Positive Predictive value (PPV): is the probability of the 
person of having the disease when the test is positive. 
 
Positive Predictive value = True positive/ True positive + False positive 
 
Definition of Negative Predictive value (NPV): is the probability of the 
person not having the disease when the test is negative.  
 
Negative Predictive value (NPV) = True negative/True negative + False 
negative 
 
Diagnostic efficiency: is the relation between all true examination results 
and the total patients' population results. 
 
Diagnostic efficiency = True positive + True negative/ Total number of 
examinations 
 
False positive rate = False positive/ False positive + True negative 
 
False negative rate = False negative / False negative + True positive 
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3. Results 
 
3.1. Analysis of Patients' Characteristics 
 
150 examinations were performed in a total of 119 patients (outpatients 
as well as inpatients) from January 1999 till June 2000. The population 
comprised 88 males (74%) and 31 females (26%). Mean age ± SD, age 
range, number of examinations as well as rate of examination per patient 
are shown in Table 3. 
 
Table 3. Gender, Age Distribution and Examinations 
per Patient 
 
N 
Age Mean ± 
SD (Years) 
Age 
range 
Number of 
examinations 
Examinati-
ons/patient
Male 88 62 ± 10 36-83 115 1.30 
Female 31 61 ± 9.5 42-83 35 1.12 
Total 119 62 ± 9.8 36-83 150 1.26 
 
A total of 23 preneoplasias were diagnosed; 19 cases in males (17%) and 
4 cases in females (9%). CIS were 6/19 cases in males (31%) and 1/4 
cases in females (25%), while moderate to severe dysplasia were 13/19 
cases in males (68%) and 3/4 in females (75%) (Fig. 11). 
 
 
Fig.11. Types of preneoplasia in relation to gender 
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In 88 examinations for smoking males, the mean cigarette consumption 
was 42.7± 29.8 pack years (P/Y) while it was 30.2 ± 12.9 P/Y in 20 
examinations for smoking females with a total of 17 cases of preneoplasia 
occurred among the "smokers" group. Among the 42 non-smokers of 
both sexes with other risk factors, there were 6 cases of preneoplasia. 
There was no statistical difference between both groups regarding early 
lung cancer cases (P< 0.48) Table 4. 
 
Table 4. Mean cigarette consumption in P/Y and its 
relation to diagnosed preneoplasias  
 Non-
smokers 
Smokers Average smoking for 
examined cases (P/Y) 
Males 27 88 42.7 ± 29.8 
Females 15 20 30.2 ± 12.9 
Total 42 108 40.4 ± 27.9 
Preneoplasias 6/42 17/108  
 
Many patients had repeated examinations mainly in the follow up of 
previous atypical histopathology/cytology results or for follow up of 
resected for cure lung cancer. The majority of patients (82%) had one 
examination only while a minority had 3 (2%) or 4 (3%) examinations 
(Table 5).  
 
Table 5. Frequency of Bronchoscopic Examinations/ 
Patient 
Number of 
examinations/Patient 
Number of 
patients 
Final number of 
examinations 
1 98/119  (82%) 98 
2 15/119  (13%) 30 
3 2/119  (2%) 6 
4 4/119  (3%) 16 
Total 119 150 
 
A total of 56 examinations (38%) were carried out for high-risk patients 
for LC presenting with ± bronchial symptoms i.e. heavy smokers with 
positive family history of lung cancer, occupationally exposed workers 
such as uranium miners, with a change in symptoms like recurrent 
unexplained hemoptysis or patients with COPD. The group with previous 
sputum atypia bronchoscoped to search for their occult LC lesions was 
the second largest group comprising 51 patients (34%). 36 
bronchoscopies (24%) were done as follow up of resected for cure LC. 
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Among the group miscellaneous, 7 patients (4%) were recruited with 
upper respiratory or digestive tract malignancies, implying a higher risk 
for developing early lung cancer (Fig 12). 
 
 
Fig. 12. Number of examinations performed for different  
               indications 
 
The highest percentage of preneoplasia was detected in the group with 
previous atypia in bronchial secretion (23%). In the other groups, the rate 
was nearly similar ranging from 14% for miscellaneous group to 11% for 
each group of patients in follow up of resected for cure LC as well as 
patients with high-risk for LC. (Table 6). 
 
Table 6. Distribution of Positive Cases of 
Preneoplasia per Indication 
Indication for AF examination Number of positive cases 
1. Previous atypical sputum results 12/51 (23%) 
2. High risk, clinically suspected 
    patients for developing LC 
6/56 (11%) 
3. Follow up of resected for cure LC 4/36 (11%) 
4. Miscellaneous 1/7 (14%) 
    Total 23/150 (15%) 
 
3.2. Analysis of AIC Results: 
 
Whereas representative sputum specimens were obtained in only 87% 
(130/150) of the patients included for AIC examination, all bronchial 
washings were satisfactory for AIC assessment. On evaluating the 2cDI 
as a dependable measure of DNA aneuploidy of airway secretions, the 
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mean value for truly positive cases were 0.171±0.05 in sputum samples 
and 0.183±0.05 in bronchial washings. On the other hand, the mean 
values for truly negative cases were 0.138±0.039 for sputum and 
0.138±0.037 for washings representing highly significant difference 
between truly positive and truly negative cases with P<0.0005 Table (7). 
 
Table 7. Evaluation of AIC Results 
 Number of 
representative 
samples 
2cDI     
(mean ±SD)  
true positive 
2cDI  
(mean ± SD) 
true negative 
P-value 
Sputum 130/150 (87%) 0.171 ± 0.05 0.138 ± 0.039 P < 0.0005 
Br. Wash 150/150 (100%) 0.183 ± 0.05 0.138 ± 0.037 P < 0.0005 
 
In 5 CIS cases of 7 (71%), a suspicious sample was correctly identified 
by AIC with a mean 2cDI of 0.21 ± 0.055 for all CIS cases while AIC 
was only suspicious in 9 cases of moderate to severe dysplasia out of 16 
(56%) with a mean 2cDI of 0.16 ± 0.056 for all dysplasia cases showing a 
highly significant difference (P<0.0005) between 2cDI means in 
diagnosing both types of preneoplasias (Table 8). 
 
Table 8. Correlation of Cytometric Diagnosis with 
Histopathological and/or Cytological Diagnosis 
 
CIS 
Moderate-Severe 
Dysplasia 
 
AIC Suspicious 5/7  (71%) 9/16  (56%) 14/23 
AIC Non-suspicious 2/7  (29%) 7/16  (44%) 9/23 
Total 7 16 23 
Mean 2cDI ± SD 0.21 ± 0.055 0.16 ± 0.056 P <0.0005
 
Excluding the 20 non-representative sputum samples for AIC 
examination that were representative in bronchial washings sampling, the 
sensitivity of both methods as well as the specificity in 130 cases showed 
no significant difference with a P<0.5 for both (Fig. 13). 
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Fig. 13. Sensitivity and specificity of AIC in sputum vs  
                bronchial washings 
 
3.3. Analysis of Endoscopic Results: 
 
Whenever a suspicious lesion in WLB and/or AF mode was detected, 
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examinations out of 150, suspicious lesions could not be detected so 
biopsies were not taken. In 50 examinations (33%), only one biopsy was 
taken, 2 biopsies in 7 examinations (4%) and 3 biopsies in 3 examinations 
(2%). A total of 73 representative biopsies were taken and evaluated 
histopathologically with an overall rate of 0.48 biopsy/examination. In 
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preneoplastic lesions diagnosed in two different lobes which would be 
reflected on further management measures but not on the rate of detecting 
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than on a per lesion analysis for lack of consequences (Table 9). 
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Biopsy rate is a good indicator for frequency of finding suspicious 
lesions. It was highest in patients with previous atypical sputum results 
undergoing meticulous search for the responsible lesion with a rate of 
0.78 biopsy/bronchoscopic examination followed by the miscellaneous 
group at a rate of 0.42 biopsy/examination. In the high risk group of 
patients, the rate fell to 0.35 biopsy/examination and further in the 
patients of resected for cure lung cancer (0.27 biopsy/examination) 
(Table 10). 
 
Table 10. Biopsy Rate per Indication 
Indication for AF examination 
Number of biopsies 
per indication 
Biopsy 
rate 
1. Previous atypical sputum results 40/51 0.78 
2. High risk, clinically suspected 
    patients for developing LC 
20/56 0.35 
3. Follow up of resected for cure LC 10/36 0.27 
4. Miscellaneous 3/7 0.42 
    Total 73/150 0.48 
 
The final histocytological results of different preinvasive lesions were 
compared to the suggested image classification under WLB and or AF. 
Identifying moderate to severe dysplastic lesions, a significantly higher 
sensitivity for WLB+AF (88%) than WLB alone (44%) was found (P< 
0.01). On the other hand, their was no significant difference identifying 
CIS between both modes with a sensitivity of 86% for WLB+AF to 57% 
only for WLB alone (P<0.27) (Table 11). 
 
Table 11. Image Classification in different 
Preneoplasias 
Suspicious image in 
Moderate-
Severe dysplasia
CIS Total 
WLB alone not AF 0/16 (0%) 1/7  (14%) 1 
AF alone not WLB 7/16  (44%) 2/7  (29%) 9 
WLB+AF together 7/16  (44%) 3/7  (43%) 10 
None of them 2/16  (12%) 1/7  (14%) 3 
Total WLB suspicious 7/16  (44%) 4/7  (57%) 11/23 
Total WLB+AF suspicious 14/16 (88%) 6/7  (86%) 20/23 
Total preneoplasias 16 7 23 
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3.4. Evaluation of all methods combined:  
 
Of 24 lesions diagnosed in 23 patients as preneoplasia on 
histopathological and/or cytological basis, 10 were found to be moderate 
dysplasia, 7 severe dysplasia and 7 carcinoma in situ. In one patient, 
carcinoma in situ as well as severe dysplasia were diagnosed in two 
different sites which would influence measures of further management 
but not the rate of preneoplasia detection. Combining AIC, WLB and AF, 
there is a sensitivity of 100%. 3 cytologically diagnosed preneoplastic 
lesions could not be localized. The data of These three patients, marked 
by (*) were not completed because of non-compliance (Table 12). 
Table 12. Characteristics, Localization, AIC and 
bronchoscopic data of Patients with Preinvasive Lesions 
Patient 
No. 
Age 
(ys) 
Gender Site Histo/Cytol ASC WLB AF 
1 75 M LB6 SD -ve +ve +ve
2 73 F MK SD -ve +ve +ve
3 65 M Trachea MD +ve -ve +ve
4 70 M RB1-2 MD +ve +ve +ve
5 79 M RB6 MD +ve -ve +ve
6 63 M LB6 MD +ve +ve +ve
7 48 F MLK MD -ve +ve +ve
8 68 F LB6 MD -ve +ve +ve
9 66 M Stump SD +ve -ve +ve
10 70 M LB7 CIS -ve +ve +ve
11 64 M RULB CIS +ve +ve -ve 
12 59 M LB3 SD -ve -ve +ve
13 46 M RB6 CIS +ve -ve +ve
14 67 F LB3 CIS +ve +ve +ve
15 76 M RB1 MD -ve +ve +ve
16 46 M RB4-5 MD -ve -ve +ve
17 69 M LB6 MD +ve +ve +ve
18 57 M LUL SD -ve +ve +ve
19 70 M RB8 CIS +ve -ve +ve
20 57 M 
RUL, 
LB3 
CIS 
SD 
-ve   
-ve 
+ve    
-ve 
+ve  
+ve
21* 60 M -ve MD +ve -ve -ve 
22* 61 M -ve CIS +ve -ve -ve 
23* 56 M -ve SD +ve -ve -ve 
MD= Moderate dysplasia; SD= Severe dysplasia; CIS= Carcinoma in 
Situ; M= Male; F= Female; +ve = Positive; -ve = Negative 
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Per patient analysis of the final results revealed sensitivity of WLB alone 
to be 48 % (11/23) while by adding AF, the sensitivity improved up to 
87% (20/23). A distinguished finding was the 100% sensitivity reached 
by adding AIC to both WLB+AF while specificity decreased from 61% 
for WLB+AF to 55% for WLB+AF+AIC all together. The positive 
predictive value was the highest for AIC (45%) but showed no difference 
between WLB alone (33%), WLB+AF (28%) and WLB+AF+AIC (28%) 
(P<0.39). The negative predictive value ranged from a highest value of 
100% with WLB/AF/AIC together to a lowest value of 89% with WLB 
alone (Table 13). 
 
Table (13) Sensitivity, Specificity, Positive Predictive 
Value and Negative Predictive Value of all Methods 
separately and combined 
 AIC 
Br. Wash  
WLB WLB/AF 
WLB/AF/
AIC 
Sensitivity 61% 
(14/23)  
48% 
(11/23)  
87% 
(20/23)  
100% 
(23/23) 
Specificity 87% 
(110/127)  
83% 
(105/127) 
61% 
(77/127) 
55% 
(70/127) 
*PPV  45% 33% 28% 28% 
**NPV 92% 89% 96% 100% 
PPV, Positive predictive value; NPV, Negative predictive value 
 
The improvement in the relative sensitivity of WLB+AF vs WLB alone 
was 1.8 (95% confidence interval 1.4 - 2.47). Also, the improvement in 
relative sensitivity of WLB+AF+AIC methods used was significantly 
better in relation to AIC alone (1.64) but with minimal improvement in 
relation to WLB/AF (1.15). As regards the relative specificity, there was 
always decreased specificity for combined methods (Table 14). 
 
 
 
 
 
 
 
 
 
 
_________________________________________________________________________Results 34
Table (14) Relative Sensitivity and 95% Confidence 
Interval (95% CI) 
 (WLB+AF)/ 
(WLB alone)
(WLB+AF+AIC)/
(WLB+AF) 
(WLB+AF+AIC)/
(AIC alone) 
Relative 
Sensitivity 
1.8 1.15 1.64 
95% CI 
Sensitivity 
1.4 - 2.47 1.02 - 1.28 1.24 - 2.21 
Relative 
Specificity 
0.73 0.90 0.63 
95% CI 
Specificity 
0.58 - 0.92 0.89 - 0. 92 0.50 - 0.81  
 
Final evaluation showed a diagnostic efficiency of 83% for AIC, 
decreased to 77% with WLB alone, 65% for WLB combined with AF and 
62% for all methods combined. The false negative rate was highest with 
WLB alone and improved up to 0% false negative detection on evaluating 
WLB+AF+AIC together with a relatively high false positive rate of 45% 
(Fig. 14). 
 
 
Fig. 14. Diagnostic efficacy, false positive and false negative  
              rates 
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3.5. Follow up results: 
 
a) Patients with CIS: Of 7 cases diagnosed as CIS, there were 3 cases 
with complete remission in a 6 months period, one case progressed to 
invasive cancer and 3 non-compliant patients with no available follow 
up data. Of the 3 patients in full remission, 2 were treated with ND-
YAG Laser alone. One of the CIS cases persisted after laser, full 
remission was acquired after brachytherapy. The patient who 
developed invasive cancer was functionally inoperable and 
progression occurred in spite of ND-YAG laser therapy (Table 13). 
 
b) Patients with moderate-severe dysplasia: Of 16 cases diagnosed as 
moderate-severe dysplasia, 9 cases had a complete remission in 6 
months period on steroid inhalation, a case of moderate dysplasia 
presented after 8 months failed follow up with invasive cancer and 6 
non-compliant cases with no available follow up data (Table 15).     
 
Summarized there are 12 cases of full remission out of 14 
compliant patients (86%) on the mentioned scheme for early lung cancer 
management while there were only 2 cases (14%) that progressed to 
invasive cancer. 
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Table 15. Results of Follow up for Diagnosed 
Preneoplasias 
Patient 
Age 
(ys) 
M/
F 
Site of 
Lesion 
Histo/
Cytol 
Therapy Outcome 
1 75 M LB6 SD Steroid Inhalation. Full remission 
2 73 F MK SD Steroid Inhalation Full remission 
3 65 M Trachea MD Steroid Inhalation Full remission 
4 70 M RB1-2 MD Steroid Inhalation Full remission 
5 79 M RB6 MD 
Steroid Inhalation + 
NC 
Invasive cancer 
6 63 M LB6 MD Steroid Inhalation Full remission 
7 48 F MLK MD Steroid Inhalation NC 
8 68 F LB6 MD Steroid Inhalation NC 
9 66 M Stump SD Steroid Inhalation Full remission 
10 70 M LB7 CIS EB Laser Full remission 
11 64 M RULB CIS EB Laser Invasive cancer 
12 59 M LB3 SD Steroid Inhalation Full remission 
13 46 M RB6 CIS EB Laser NC 
14 67 F LB3 CIS 
EB Laser + 
Brachytherapy 
Full remission 
15 76 M RB1 MD Steroid Inhalation NC 
16 46 M RB4-5 MD Steroid Inhalation Full remission 
17 69 M LB6 MD Steroid Inhalation NC 
18 57 M LUL SD Steroid Inhalation Full remission 
19 70 M RB8 CIS EB Laser NC 
20 57 M 
RUL, 
LB3 
CIS 
SD 
EB Laser & 
Steroid Inhalation 
Full remission 
Both 
21* 60 M -ve MD Steroid Inhalation NC 
22* 61 M -ve CIS EB Laser NC 
23* 56 M -ve SD Steroid Inhalation NC 
 
MD= Moderate dysplasia; SD= Severe dysplasia; CIS= Carcinoma in 
Situ; M= Male; F= Female; NC= Non-Compliant; EB Laser = 
Endobronchial Laser Therapy 
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Discussion 
 
4.1.  Size of the problem:  
 
The incidence of lung cancer worldwide is often described as reaching 
epidemic proportions despite the fact that for 90% of these cancers, the 
cause is known and preventablecigarette smoking (23). Approximately 
10% of heavy smokers will develop lung cancer in the long run (16). 
Even if all tobacco use were immediately stopped, there would still be 
many thousands of new lung cancers over the next ten to twenty years, as 
the risk of contracting the disease doesn't drop on smoking cessation to 
the non-smokers' level (79). 
  
There is no doubt that the earlier lung cancer is detected, the better 
are the patient's chances of survival (57). Naruke et al. in 1997 reported a 
100% survival rate when lung cancer was diagnosed in stage 0 while it 
was only 68.5% for stage I and continued to decrease to 46.9% for stage 
II, 26.1% for stage IIIA, 11.2% for stage IV and down to 9% for the 
poorest prognosis stage IIIB (60). So, there is a clear inverse proportion 
between cancer stage at the time of diagnosis and the survival rate. 
 
 Intraepithelial (preinvasive) neoplasia starts with a molecular 
phase, in which the epithelium is morphologically normal but is 
undergoing genomic instability, followed by a morphologic phase, in 
which aberrant proliferative foci with nuclear and cytologic changes, 
termed dysplasia, and carcinoma in situ form the basis for the 
microscopic diagnosis of preinvasive or intraepithelial neoplasia (14). 
  
Despite intensive research, /clinical screening trials, and enormous 
therapeutic costs, there has been little improvement in survival in the last 
30 years. The ineffectiveness of current treatments and the observation 
that early stage disease has the best outcome has led to a belief that the 
early detection of the disease offers the best chance of survival. 
 
4.2. Inefficiency of conventional methods: 
 
Carcinoma in situ and microinvasive cancers of the central bronchi 
present a challenging diagnostic problem. These cancers mostly are first a 
few cell layers thick (0.2-1mm) and a few millimeter in surface diameter 
(85). Because of this, the lesion may not be recognized by conventional 
methods previously tried to early diagnose LC (Fig 15). 
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Fig. 15 CIS in carina of medial segment of Rt. lower lobe  
 
For decades, the diagnosis of early lung cancer depended upon 
conventional methods of low sensitivity. Chest x ray, as expected, is 
unable to detect early central LC lesions in its intra-epithelial stages. Its 
use alone as a method of screening for this type of cancer will cause a 3 
years delay in its diagnosis if not combined with sputum cytology (55). 
Sputum cytology was found to be of low sensitivity (40%) in detecting 
occult stage I LC in the screening studies conducted by Johns Hopkins 
Lung Project, Mayo Lung Project and the Memorial Sloan-Kettering 
National Lung Program 20 years ago. Also, regarding conventional white 
light bronchoscopy, detection and localization of dysplasia and carcinoma 
in situ was found not to exceed 29% (84). 
 
4.3. Failure of early screening studies: 
 
Based on the fact that the earlier lung cancer is detected, the better its 
prognosis, large screening trials were conducted in the 70's using various 
combinations of sputum cytology, CXR and conventional bronchoscopy, 
in an effort to increase survival in high-risk patients. For a number of 
reasons, including antiquated technologies, these trials failed and health 
authorities turned to anti-smoking measures as the only viable alternative 
to combat lung cancer. But as the evidence mentioned above shows: even 
if anti-smoking strategy were strictly followed, lung cancer will continue 
its steep rise for another two decades before it will finally levels off and 
start to drop.  
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To summarize, it was found that the value of chest x-rays in screening is 
debatable, no added advantage for using sputum cytology could be 
proved and both methods did not effectively influence the mortality rate 
of lung cancer. Screening for lung cancer was abandoned as a waste of 
resources (4, 27). 
 
 Meanwhile, new diagnostic methods, discussed here, have re-
awakened hopes for effective early LC screening. Hence a two pronged 
strategy against lung cancer may now be implemented: on one hand, 
redoubling efforts to reduce smoking in adults and preventing the youth 
from starting the habit. On the other hand, instituting studies using new 
promising sensitive technologies for early lung cancer detection. In 
December 1998, an international conference for prevention and early 
diagnosis of lung cancer was held in Varese, Italy that was attended by 18 
world-wide distinguished scientists in this field from eleven countries. A 
conclusion statement that was agreed unanimously stressed upon the risk 
of this global lung cancer epidemic and its deadly potential, the pressing 
need for effective screening measures and the favorable outcome of case 
finding studies when lung cancer is early detected (34). 
 
4.4. Discussion of results: 
 
In a case finding study involving 119 patients - performed in 150 
examinations- at high risk for LC, we tested the hypothesis, whether by 
automated image analysis of sputum and bronchial washings and by the 
addition of AF to conventional bronchoscopy, a significant increase in the 
diagnosis of severe dysplasia and CIS could be achieved.  
  
As previously noted, patients for this study were recruited with a 
high risk factor for lung cancer. Patients were either heavy smokers, 
occupationally exposed as uranium miners, having COPD, sputum atypia, 
undergoing follow up of previously resected for cure lung cancer or with 
upper aerodigestive tract cancer (Fig.12). These risk factors may be 
responsible for the high preneoplasia rate among non-smokers (Table 4.). 
This concurs with the recommendations, recently published by Kennedy 
and coworkers in 2000 at SPORE in University of Colorado, 
recommending narrowing of case finding studies to such higher risk 
group of patients with smoking history >30 P/Y and COPD. They hope to 
identify, through these measures, a suitable target population for future 
screening programs (41).  
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Based on histopathology and/or cytology, 23 preneoplasias (16 cases of 
moderate to severe dysplasia and 7 carcinomata in situ) were diagnosed. 
A relative sensitivity of WLB/AF to WLB alone proved to be 1.8. The 
sensitivity of combined WLB/AF/AIC proved to be 100% (23/23) for 
detecting all preneoplasia cases. Although the use of AF, the 
preneoplastic lesions were not localized in 3 cytologically diagnosed 
cases out of 23 (Table 12). The highest percentage of preneoplasia was 
detected in the group with previous atypical bronchial secretion results 
(23%) which was the same finding in a previously published study by 
Khanavkar et al. 1998 (42). This group had the highest rate of biopsy 
taking per examination (0.78) in the current study, which reflects the 
frequency of finding suspicious lesions and consequently explains this 
high detection rate (Table 10). After excluding 9 non-compliant patients 
from follow up analysis, a success rate of 12/14 cases (86%) in treating 
preneoplasia was achieved. 
 
In this series, 150-sputum specimens as well as bronchial washings 
were collected for AIC examination. Sputum samples were collected 
without induction aiming to evaluate the detection rate by a simple 
technique that may be applicable for future screening programs. In 13% 
of cases (20 patients), sputum was found to contain a minimal amount of 
respiratory tract cells and was classified as non-representative for 
evaluation while all bronchial washings were representative (Table 7). 
This may emphasize the importance of sputum induction and its value in 
such circumstances. Such simple technique should be routinely used in 
any future sputum-examination studies. After excluding the 20 non-
representative cases from evaluation, the sensitivity of bronchial 
washings vs sputum for AIC were 61% and 62% respectively showing no 
statistically significant difference (P<0.5). Similarly, no difference was 
observed in specificity of bronchial washings (87%) and sputum 
specimens (85%) (P<0.5) (Fig. 13). The overall diagnostic efficacy for 
AIC in detecting preneoplastic lesions of the lung was 83% (Fig. 14). 
 
Many investigators have shown that the more advanced the 
malignancy grade of a certain tumor, the higher and more widely 
dispersed is the DNA content of the tumor cell nuclei (43, 63). These two 
changes raise the mean square deviation of the nuclear DNA content from 
the diploid and thereby increase the 2cDI (13).   
 
On evaluating 2cDI as a measure for DNA aneuploidy, a highly 
significant difference (P<0.0005) could be found between truly positive 
and truly negative cases. The mean 2cDI for true positive cases by 
bronchial washings was 0.183 ± 0.05. The other parameter we used for 
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evaluating suspicious nuclei was the virtual morphological diagnosis of 
suspicious nuclei, which didn't usually correlate with the 2cDI value in 
this group of patients. Further research will have to go into trying to 
redefine threshold values for 2cDI in preneoplasia that is different from 
values for invasive cancer (Table 7). 
 
By evaluating the different preneoplastic stages separately, it was 
found that AIC correctly identified 71% of CIS cases with a mean 2cDI 
of 0.21 ± 0.055 while the detection rate for dysplasia was 56% with a 
mean 2cDI of 0.16 ± 0.056 showing a highly significant difference in 
detection rate between both types of lesions (P<0.0005). This supports 
the observation that more advanced lesions present with more 
pronounced abnormalities in nuclear structure, which will be 
consequently reflected on cellular proliferation rate and 2cDI (Table 8). 
  
In the current study, white light bronchoscopic examination was 
always followed by autofluorescence bronchoscopy. Some authors who 
tested sensitivity and specificity of each mode alone have done 
randomization of the sequence of different modes. They proved no 
difference in the rate of early detection irrespective of the sequence (80). 
AF alone will miss some endoscopic information provided by WLB as 
submucosal tumor growth. AF should be used as a complementary 
examination to WLB and not exclusively. To assess the additional benefit 
added by AF, it is appropriate to start examination with WLB and to 
compare localization rate of WLB alone to WLB+AF.    
 
Histo/cytologially confirmed moderate and severe dysplasias vs 
CIS results were correlated to their WLB and /or AF image classification 
and the sensitivity for each preneoplasia type were determined. There was 
a significant difference between WLB+AF vs WLB alone in detecting 
moderate/severe dysplasia lesions with a sensitivity of 88% and 44% 
respectively (P<0.01). On the other hand, there was no statistical 
difference between both methods in detecting CIS with a sensitivity of 
86% for combined modes vs 57% for WLB alone (P<0.27) (Table 11).  
 
In 1993, Lam et al. calculated the average red and green intensities 
of autofluorescence images for normal bronchial mucosa and 
preneoplastic lesions (47). They concluded that there was a significant 
difference between fluorescence intensities in images of normal and 
preneoplastic lesion but there was no such difference between dysplasia 
and CIS. Yet, in partial support to the current study results, Lam et. al in 
1994 retrospectively correlated different preneoplasia grades to image 
classification without further statistical interpretation regarding difference 
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between both modes in detecting preneoplasia grades. After analyzing 
their data, it was found that they had a highly significant difference 
between WLB+AF vs WLB alone in detecting moderate/severe dysplasia 
with a rate of 63/78 and 30/78 respectively (P<0.001) (48). In contrast to 
the results of this study, There was a significant difference regarding CIS 
detection with a rate of 32/35 for WLB+AF vs 14/35 for WLB alone 
(P<0.001).  
 
To summarize, the current study supports that there is a statistically 
significant difference between WLB+AF vs WLB alone in detecting 
moderate to severe dysplasia (P<0.01) while such difference was not 
evident in case of CIS lesions. This finding is comparable with some 
previous studies. The explanation of this difference is not clear. The inter-
observer variability is an important factor. Also, long term use of AF 
trains the observer's eye for subtle endoscopic changes in WLB as well. 
Finally, there are more marked endoscopic findings in WLB for CIS than 
dysplasia. 
 
  In this study, the relative sensitivity of WLB+AF vs WLB alone 
was found to be 1.8 for early lung cancer lesions and preneoplasia with a 
sensitivity of 87% (20/23) vs 48% (11/23) respectively (P<0.005). Thus, 
the addition of AF to WLB resulted in a significant increase in detection 
rate of early lung cancer lesions that would otherwise be missed if AF 
were not used. By adding AIC for bronchial washings, relative sensitivity 
of WLB+AF+AIC vs WLB+AF was improved by 1.15 with a sensitivity 
of 100% (23/23) for all methods together. This comes in support of the 
complementary concept between different methods of early LC detection 
(Tables 13,14).  
 
  Three lesions confirmed by cytology could not be localized 
successfully. This may be because these lesions were possibly located in 
the subsegmental airways that are accessible to bronchial washings but 
not to the bronchoscope (silent area of the lung), or they may represent 
false negative lesions for WLB/AF. This phenomenon is known in other 
studies in which positive control biopsies were found in non-suspicious 
endoscopic areas. Follow up data for these three cases could not be 
obtained because of the patients' non-compliance  (Table 12).   
 
The positive predictive value for both WLB+AF and 
WLB+AF+AIC was 28%, which was comparable to that of WLB alone 
(33%). On the other hand, the negative predictive value is ideal, ranging 
from 89% for WLB alone to 96% for WLB+AF and up to 100% for 
WLB+AF+AIC together. Although the low positive predictive value is 
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not ideal, the increased sensitivity as well as negative predictive value of 
the fluorescence examination combined with AIC is a true advantage 
(Table 13). 
 
In 1993, Lam et al. encouraged the concept of a two-stage 
screening approach where a simple, highly sensitive, but not necessarily 
specific, initial test is followed by a more involved, highly specific 
confirmatory test (50). In the current study, the relative specificity of 
WLB+AF vs WLB alone was found to be 0.73 for early lung cancer 
lesions with a specificity of 61% and 83% respectively. Along with that, 
the relative specificity of WLB+AF+AIC vs WLB+AF was 0.90 with 
55% of the former. Thus, the addition of AF to WLB resulted in a 
significant decrease in specificity from 83% to 61%. In contrast, adding 
AIC to WLB+AF led to no significant deterioration in specificity than 
before with 55% vs 61% (Tables 13,14).   
 
This decrease in specificity due to false positive results may be 
attributed to the assumption that the autofluorescence pattern of bronchial 
mucosa may reflect molecular genetic abnormalities beyond the threshold 
of the microscopic abilities of the pathologist (46). This is supported by 
Venmans et al. 2000 who described two cases of severe dysplasia and 
another of carcinoma, which were previously and frequently classified as 
AF suspicious but biopsies at that location had revealed normal mucosa 
only. Progression occurred later on in the previously AF suspected sites 
(81). These observations are considered a rich field for future controlled 
studies concerning the correlation between AF image classification and 
molecular genetic abnormalities. 
 
4.5. Comparison with previous international studies: 
 
There is no available similar study up till now to evaluate the feasibility 
of combined automated image cytometry and autofluorescence 
bronchoscopy in improving early lung cancer detection and localization. 
A comparison between the results of this study for each method 
separately with any comparable studies available will be commented on. 
 
Since the development of the LIFE® device, several studies from 
international centers have been published on results and evaluation of the 
LIFE system in early detection of precancerous lesions and CIS. Two 
large studies were reported from Lam et al. in 1993 and 1998 (47, 46). 
Also, a large prospective study were published by Khanavkar et al. in 
1998 from the Research Institute for Diagnosis and Treatment of Early 
Lung Cancer (RIDTELC), in Bochum, Germany (42) and there are 
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data by Venmans et al. from the Free University Hospital of Amsterdam 
in 1999 (82). Kurie et al. from Texas University, Houston reported his 
results in 1998 (44) as well as Kato et al. 1998 (39), Yokomise et al. 1997 
and Kakihana et al. 1999 from Japan (86, 37). 
 
The results of the above mentioned studies regarding number of 
positive lesions, sensitivity, specificity, relative sensitivity, positive 
predictive value and negative predictive value are summarized together 
with the current study's data (Table 16.): 
 
Table 16. Comparison of available results from 
previous autofluorescence studies with the current 
study 
Author 
+ ve 
lesions/
total 
WLB 
Sens.-
Spec 
WLB+AF 
Sens.- 
Spec 
Relative 
sens. 
PPV 
WLB-
W+AF 
NPV 
WLB-
W+AF 
Lam 1993 
(47) 
77/328 
48.4% 
- 94% 
72.5% 
- 94% 
1.5 - - 
Lam 1998 
(46) 
142/700 
37.3% 
-? 
75% 
-? 
2.0 
0.39 
-0.33 
- 
Khanavkar 
1998  
(42) 
38/194 
31.8% 
-75.4% 
86.4% 
-31.4% 
2.7 - - 
Venmans 
1999  
(82) 
79/681 
59% 
-85% 
85% 
-60% 
1.4 
35% 
-23% 
94% 
-97% 
Kurie 1998 
(44) 
0/245 - 
43.3% 
-57.3% 
- 
? 
-24.8% 
? 
-75.7% 
Kato 1998 
(39) 
73/213 
51% 
-59% 
93% 
-65% 
1.8 
76% 
-66% 
- 
Yokomise 
1997  
(86) 
19/51 
65% 
-71% 
90% 
-77.4% 
1.4 - - 
Kakihana 
1999  
(37) 
79/147 
51% 
-54% 
88% 
-56% 
1.7 
62% 
-71% 
- 
Current 
study 2000 
23/150 
48% 
-83% 
87% 
-61% 
1.8 
33% 
-28% 
89% 
-96% 
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The results of the current study are comparable with previous 
international studies to a large extent. There are, however, certain 
differences in the study design as well as the methods of statistical 
analysis that need to be considered. 
 
Nearly all the previous studies in this comparison included patients 
with manifest invasive endobronchial tumors in their study group with the 
aim of detecting early lung cancer lesions in other sites of the bronchial 
tree as these patients are at higher risk for harbouring a second primary 
LC. These pioneer studies aimed mainly at testing the relative sensitivity 
between WLB+AF to WLB alone in detecting ELC lesions because, at 
that time, AF itself was still under trial. The AF used was LIFE® in all 
studies except that of Kakihana et al. 1999 who used the SAFE 1000 
device, which uses a conventional Xenon light with a special filter that 
delivers only the wavelength of 420-480 nm as an excitation light (37).  
 
In this study, sensitivity and specificity were tested against 
histopathological and/or cytological diagnosis as the gold standard. 
Ideally speaking, statistically unbiased estimates of sensitivity and 
specificity were not possible to obtain because serial sections of the entire 
tracheobronchial tree would need to be examined after bronchoscopic 
procedures for these to be defined. In all studies mentioned, control 
biopsies were taken from different predetermined segments after proving 
WLB and AF negative. This was done to determine true negative cases 
and to calculate specificity. Some studies reported no histopathologically 
positive control biopsies for preneoplasia (80), others detected 
insignificant number of positive control biopsies (48, 86) while in only 
one study, no difference was found between biopsies taken from 
predetermined sites and AF guided (44).  
 
In the current study, control biopsies were not taken but bronchial 
washings for conventional cytology instead. Control biopsies were not 
done, as it does not provide the ideal solution for calculating sensitivity 
and specificity because some sites of bronchial mucosa that escape 
biopsies may harbour preneoplasia. Also, it can't detect peripheral 
preneoplastic lesions in the bronchoscopically silent subsegments - a true 
advantage for conventional cytology. Considering repeated AF follow up 
examinations of these high-risk patients, biopsy sites will leave 
permanent AF suspicious area. Even if some control biopsies were found 
to be preneoplastic, this would not be reflected on the study 
recommendations, as this couldn't be considered a standard investigation 
to be followed, as bronchial washings for cytology. 
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In their statistical analysis, some authors calculated sensitivity and 
specificity of these systems in detecting moderate dysplasia and worse 
including invasive lung cancer, which was sometimes in large numbers as 
15/19 and 40/142 (86, 46) . This will increase the sensitivity of WLB in 
relation to AF as WLB can be considered to be almost 100% sensitive in 
diagnosing invasive tumors. On the contrary, others calculated their 
results for the detection of metaplasia and mild dysplasia, which is 
actually not an indication for AF use (44). 
 
In the current study, statistical analysis of data was done on a per 
patient basis only while all other studies calculated their results mostly on 
a lesion-by-lesion analysis rather than a per patient analysis. a per lesion 
analysis is ideal for studying of AF sensitivity itself in identifying 
individual preneoplastic lesions that may be many lesions in a single 
patient with already diagnosed invasive LC.   
 
Difference in experience between examiners and pathologists may 
explain the differences in results between studies. In the multi-centric 
study (eight centers) (46), a relative sensitivity of 6.3 was calculated for 
moderate to severe dysplasia and CIS lesions between WLB+AF and 
WLB alone with a detection rate of only 9/102 for WLB in comparison to 
55.9% for the combined method in detecting such lesions. This puts a big 
question mark on the experience of the responsible examiners in these 
centers regarding the WLB endoscopic diagnosis.  
 
The study of Kurie et al. 1998 used a historic control group for 
WLB to compare it with the study group for AF. In addition, a reference 
pathologist found 18 dysplastic lesions versus the original eight detected 
by the study's pathologist in an independent review of the biopsy 
specimens magnifying the problem of different pathological 
interpretation between different observers. Finally, 46% of the study 
population were women, which may explain the low yield of preneoplasia 
in this study (44). 
 
Venmans et al. 1999 randomized the sequence of AF/WLB. He 
found no difference in the detection rate between starting with either 
method. Also, he differentiated the results of the first half of 
examinations from the second half trying to identify the learning effect. 
He found that results obtained in the second to be better than the first 
indicating a learning effect in using AF (82). Comparing our results and 
that published by Khanavkar et al. 1998, we realize that there is 
improvement in all parameters of WLB and AF in the current study, with 
the exception of AF sensitivity that was nearly the same, indicating a 
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positive learning curve for AF in detection of subtle intraepithelial 
preneoplastic lesions (42). 
 
Kakihana et al. 1999 conducted his study with SAFE 1000 and 
reported 79 positive lesions out of 147 with 24 lesions of invasive cancer. 
He did not classify dysplasia according to severity (37).   
 
Finally Kato et al. 1998 published their results in an editorial 
comment on the method of AF in detecting ELC not describing any 
detailed analysis or study design. He mentioned that 41 sites with 
invasive cancer out of 213 total biopsy sites (39). 
 
To summarize, nearly all available studies, including the current 
one, proved the superiority of combined WLB+AF to WLB alone in 
detecting preneoplasia of bronchial mucosa. These results were 
recognized by the US Food and Drug Administration when they approved 
the LIFE® system. 
 
Regarding AIC, a study was conducted on 28 cases exhibiting 
atypical changes in sputum cytology and one case in bronchial washings. 
They reported 19 cases out of 28 proved by different diagnostic methods 
to be bronchial cancer. Of these, 17 cases proved true positive by AIC 
leaving a sensitivity of 89.5% and a specificity of 100% with a range of 3 
days to 6 months between AIC diagnosis and morphological confirmation 
by conventional methods. They concluded that DNA aneuploidy detected 
by AIC of sputum may proceed the morphological criteria of malignant 
transformation discovered by conventional cytology and or 
histopathology (7).  
 
Another group conducted their study on 142 suspicious lung cancer 
patients and 50 controls by collecting bronchial washings and correlating 
the results with the end diagnosis which comprised cytology, 
histopathology and/or post resection pathological diagnosis. they reported 
102 cases with end diagnosis of bronchogenic carcinoma with a 
sensitivity of 90% and specificity of 84% for AIC. The remarkable 
difference from our study was that the recruited patients were completely 
different regarding their inclusion criteria. Such patients with invasive 
lung cancer would be excluded from the current study, which deals 
mainly with preneoplasia detection (54). 
 
From the current study, the benefit of AIC was obvious in 
detecting DNA aneuploidy of early lung cancer nuclei. We recorded a 
sensitivity of 61% (14/23), a specificity of 87% (110/127), positive and 
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negative predictive values of 45% and 92% respectively with a total 
diagnostic efficacy of 83%. The complementary effect between AIC and 
WLB+AF in detecting early lung cancer lesions resulted in 100% 
detection of all preneoplastic lesions in the study group. These simple and 
relatively non-invasive techniques are currently under evaluation to be 
implemented in screening programs for early lung cancer in high-risk 
groups.  
 
4.6. Follow up and Management of dysplasia and CIS cases: 
 
In 7 cases of CIS, three were non-compliant and could not be evaluated. 
In 3 compliant cases out of 4 (75%), complete remission was achieved 
after endobronchial laser therapy in two of them and in one case after 
brachytherapy. In the fourth case (25%), invasive cancer developed in 
spite of laser treatment (Table 15). This comes in support to the short-
term follow up study reported in 1997, when 22% (7/32) cases of CIS 
progressed to invasive cancer in 3 months after diagnosis (76).  
 
In cases of moderate to severe dysplasia, there was only 1 case 
(moderate dysplasia) out of 16 (6%) that progressed to invasive cancer 
during 8 months after initial diagnosis. Steroid inhalation and follow up 
AIC and AF after 3 months were recommended. The patient presented 
eventually after 8 months with invasive cancer. This demonstrates that 
dysplastic lesions should be regarded as having a high potential of 
becoming invasive cancer. Venmans et al. 2000 observed a similar 
pattern when a case of severe dysplasia progressed to invasive cancer 10 
months after diagnosis. This observation puts a question mark behind the 
needed time for evolution of dysplasia to invasive cancer suggesting a 
more rapid transition (81). 
 
The outcome of other dysplasia cases was 56% (9/16) with 
complete remission, in 37% (6/16) no follow up data were available. 
Whether remission occurred spontaneously or in response to steroid 
inhalation is not clear. In 1982, Johnston reported on 43 patients out of 
135 (32%) who had "atypical cells suspicious of malignancy " in their 
sputum analysis, the follow up proved these to be due to a variety of non-
neoplastic diseases, usually inflammatory in origin (36). This comes in 
support to our suggested scheme of prescribing inhaled steroid to these 
patients in order to exclude such inflammatory etiology for dysplasia. 
 
There is no special scheme internationally agreed upon for follow 
up of diagnosed preneoplasias. Each center deals with individual cases 
according to a lot of changeable factors such as the availability of new 
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technologies in each center, skills of the treating physician in 
interventional endobronchial methods of early cancer treatment etc.  
 
Taking into consideration that dysplasia of bronchial mucosa is 
sometimes recorded in association with severe lower respiratory tract 
infection that is considered the responsible insult for such changes in 
cellular proliferation, we suggest the following scheme for preneoplasia 
management: 
 
4.6.1. Management of CIS Cases:  
 
All CIS and worse cases are already lung cancer according to TNM 
classification for international staging of lung cancer in 1986 and must be 
treated. The choice of treatment modality depends mainly upon general 
condition of the patient, his pulmonary function reserve, the degree of 
tumor invasion, tumor stage and the multi-centricity of the early tumor. A 
depleted pulmonary reserve as commonly seen in COPD cases will 
exclude surgical interference and direct the management into the 
previously discussed endobronchial treatment modalities as ND-YAG 
laser, electrocautery, cryotherapy, brachytherapy and photodynamic 
therapy.  
 
A great advantage of ND-YAG laser in this respect over other 
modalities is that it works in a non-touch technique, which reduces 
patient coughing during the procedure, keeps the Laser catheter always 
clean from debris. These advantages made ND-YAG laser the method of 
choice in RIDTEC institute for treating such lesions.  
 
In the meanwhile, surgical resection of the affected segment or 
lobe is preferred in localized lesions with acceptable preoperative 
assessment. Further follow up after either modality of treatment include 
sputum for AIC and AF examination in intervals of 3 months after 
treatment, 6 months then once yearly. 
 
4.6.2. Management of dysplasia cases: 
 
Cases of metaplasia or mild dysplasia are followed up after 3 months by 
sputum for AIC only without any need for further interference. Cases of 
moderate to severe dysplasia are given steroid inhalation for 3 months to 
exclude severe inflammation and the patient was instructed to stop 
smoking. The follow up by both sputum for AIC and AF is scheduled for 
3 and 6 months intervals. There is usually complete remission under this 
strategy but if dysplasia persists, treatment and follow up should be 
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conducted as previously mentioned in CIS. Usually endobronchial 
intervention by ND-YAG laser suffices.  
  
4.7. Implications of AIC and AF on future screening studies: 
 
The past screening studies available proved that a forward shift of stage 
distribution is possible, especially in case of squamous cell carcinoma 
with markedly increased rate of resectability (26). However, there was no 
disease-specific reduction in mortality: a gold standard of efficacy in 
screening for early fatal disease. Innovative technology advancements in 
the last few years, including AF and AIC as well as new methods of 
sputum processing (MARATHON-S) promise a worthwhile retrial of 
such screening studies.  
 
In this study, the complementary effect of both AIC for bronchial 
washings and AF mounted to a sensitivity of 100% for early lung cancer 
detection in this group of patients. The economic factor, the feasibility of 
such a screening program as well as the detection of high-risk group of 
patients that gain benefit from the program, are all important factors to be 
considered. Recently in RIDTELC, a new screening project for ELC 
detection was started in patients above 50 Ys with a smoking history of 
30 Pack/Year using AIC, Conventional cytology and CXR for detecting 
new cases as well as AF for localizing suspicious lesions. These 
techniques were chosen to be evaluated and compare its results so as to 
determine the best and most feasible combination to achieve an 
acceptable complementary effect for this task taking into consideration 
the cost-benefit ratio (59). 
 
Sputum examination for cellular atypia is a very practical and 
useful method of screening. The type of examination, method of sputum 
preparation, tumor type as well as tumor stage and location are important 
factors in determining the results. In early lung cancer cooperative study 
1984, conventional sputum cytology proved an overall sensitivity of 40% 
in detecting occult stage I lung cancer, specificity of 99% for moderate-
severe dysplasia and CIS and a specificity of 99.95% for lung cancer in 
general.  
 
In a previous study, an overall sensitivity of AIC for bronchial 
washings in lung cancer proved to be 90% with a specificity of 84% (54). 
In the current study, a sensitivity of AIC for sputum examination, without 
induction, in moderate-severe dysplasia and CIS proved to be 62% with a 
specificity of 85%. This improvement in sensitivity of sputum 
examination for AIC together with full automation of the process 
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provided an advantage for AIC over conventional cytology in screening 
for lung cancer.  
 
In 1997, Payne et al. retrospectively examined 73 slides stored 
from the Mayo screening project by AIC. 40 slides were of cases that 
developed LC after a mean of 14 months and 33 slides of normal 
controls. They described what is called Malignancy Associated Changes 
(MACs) discovered in slides of patients who developed LC later on. With 
a special trainable classifier for MACs, a correct detection rate of 77.5% 
(31/40) in cancer group and 78.8% (26/33) in non-cancer group were 
achieved. Interestingly, MACs cells disappeared after successful 
resection of the tumors- a proof of validity as a follow up of resected for 
cure LC patients (64). 
 
4.8. Other recent advances in ELC detection: 
 
Several recent advances in understanding the biology and genetics of the 
carcinogenic process have renewed hope that an early detection strategy 
may be useful. 
 
4.8.1. Monoclonal antibodies (MoAb) in Sputum: 
 
Tockman et al. in 1988 suggested that diagnostic lead time might be 
extended by adding a specialized procedure as an adjunct to sputum 
cytology (i.e., using two MoAbs directed at a difucosylated Lewis X 
epitope and a 31-kd protein) (78). Using archived sputum specimens from 
subjects who developed lung cancer after documented moderate dysplasia 
during the Johns Hopkins study, the investigators applied this procedure 
to demonstrate positive staining on smears as much as 24 to 48 months 
prior to the diagnosis of cancer by Saccommano cytology criteria.  
Studies are still underway to prospectively validate this technique. 
 
4.8.2. Genetic Advances: 
 
An increasing number of important mutations have been identified in 
lung cancer, including allelic deletions or tumor suppressor gene 
inactivation in 3p, 5q, 9p, 11q, 17p, 13q, 18q, and 22q.  At least three 
alleles appear important on 3p, with more extensive loss commonly seen 
in small cell lung cancer and less extensive loss associated with non-
small cell lung cancer. P 53 alterations appear to be nearly universal in 
solid tumors, including lung cancers.  
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Array chip technology promises to accelerate the process of identifying 
important mutations and critical patterns of mutations.  Thus, elucidating 
molecular-biological events is key to improving the sensitivity of sputum 
evaluations and may lead to effective chemoprevention strategies, as well 
as improved treatment of systemic disease. These methods are, however, 
still in experimental stages and mostly not enough validated to justify 
blinded clinical trials (41). 
 
4.8.3. Low dose CT of the chest: 
 
Improved chest imaging also may provide increased sensitivity and 
improved specificity for localizing early stage lesions of the peripheral 
lung.  Kaneko et a1. in 1996 screened 1,369 subjects with at least 20 
pack-year smoking histories using spiral CT chest examinations. They 
discovered 15 cancers (14 stage I), including 11 not detectable by plain 
chest radiographs.  Spiral CT imaging takes 15 to 30 seconds allowing 
complete chest imaging in one breath-hold. In addition, it has the 
radiation exposure of a mammogram and can pinpoint lesions as small as 
2 to 3 mm in size (38). 
 
  These newer, more sensitive technologies have led some scientists 
to raise valid concern that over identification of benign lesions may lead 
to possible over treatment morbidity, similar to that experienced with 
early CT scans.  Care must be used to resolve this issue.  Shimizu et al. in 
1995 have suggested using helical CT imaging to improve anatomic 
distinctions between nodules, vessels, bronchi, and chest wall over 
conventional CT imaging; this may reduce the incidence of false-negative 
malignant diagnoses (73). 
   
  Bronchoscopy and positron emission tomography (PET) scanning 
 the latter, however, at present prohibitively expensive - are quite benign 
and viable approaches to distinguishing between benign and malignant 
lesions preoperatively, with transthoracic needle aspiration considered 
less so because of a significant rate of pneumothoraces. Periods of 
follow-up evaluation CT scans have been used successfully to reduce 
inappropriate surgery. 
 
  Improved imaging also serves a critical role in addressing the 
increasing incidence of adenocarcinoma (often arising peripherally), as 
well as in shrinking the "silent" area of the lung i.e., the subsegmental 
airways not accessible to the bronchoscope.  
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4.9. Some ELC detection-related problems: 
 
There are some inherited problems regarding early lung cancer detection. 
These are partially related to the diagnostic methods and partially related 
to the unclear carcinogenesis and progression of preneoplasia. 
 
One of these limitations regarding used methods is the absence of 
quantitative measurements of abnormally interpreted autofluorescence 
image of a certain lesion. There are some developed systems that depend 
upon ratio fluorometry, which is a non-imaging technique that 
quantitatively measures the fluorescence in the lesions but can't 
sufficiently localize them (45). In recent imaging AF devices, The 
interpretation of autofluorescence image depends mainly upon the 
experience of the examiner and this problem is actually the main reason 
of inter-observer variability in AF interpretation. Recently, Lam et al. 
2000 presented the preliminary result of a new quantitative fluorescence 
imaging device that can alert the endoscopist to suspicious areas by 
numeric signal and an audio tone. He reported the accuracy of this new 
system in detecting small pre-invasive lesions and the ability to 
distinguish between preneoplasia and previously biopsied sites that can 
mimic it (49).  
 
Another problem was the high rate of false positive results 
regarding AIC as well as AF. Although there is an observed increase in 
detection rate, there were a non-negligible number of suspicious AIC 
and/or AF images that proved to be normal afterwards. The reason of 
false positive results with both methods is still unknown. A correct 
detection rate of 77.5% (31/40) for AIC was reported in a group of 
patients that were at that time morphologically non-suspicious but 
developed LC 14 months later (64). They concluded that AIC suspicious 
samples might be in an ongoing carcinogenesis process for a future, 
morphologically positive LC. Also, on following the outcome of a group 
of patients that were previously diagnosed as preneoplasia, it was found 
that previously classified images as AF suspicious, which proved 
morphologically negative at that time, developed morphologically 
positive preneoplasia later on (81). All these findings point out to the bad 
need of further genetic studies for deeper understanding of the 
carcinogenesis in bronchogenic carcinoma. 
 
__________________________________________Summary, Conclusions & Recommendations 54
Summary 
 
Background: Conventional methods for early lung cancer detection as 
sputum cytology and white light bronchoscopy have a very low 
diagnostic rate not exceeding 40% and 29% respectively. Automated 
image cytometry and autofluorescence bronchoscopy are novel 
techniques developed to improve the diagnostic rate of such lesions with 
promising results.  
Objectives: Can an increase in the diagnostic rate of ELC be achieved by 
combining AIC with WLB/AF examination? 
Patients and Methods: In 1999-2000, 119 high-risk patients were 
recruited in 150 examinations in a case finding study. Initial 
investigations for presenting complaints were negative for lung cancer. 
All patients submitted airway secretion for AIC and conventional 
cytology (CY), underwent white light (WLB) and AF bronchoscopy. 
Suspected lesions were biopsied and examined histopathologically. 
Positive cases were followed up after 3 and 6 months. 
Results: Based on histopathology and/or cytology, 23 preneoplasias (16 
cases of moderate to severe dysplasia and 7 carcinomata in situ) were 
diagnosed. Although the use of AF, the preneoplastic lesions were not 
localized in 3 cytologically diagnosed cases out of 23. A relative 
sensitivity of WLB/AF to WLB proved to be 1.8. The sensitivity of all 
methods proved to be 100% (23/23) for detecting all preneoplasia cases. 
After excluding 9 non-Compliant patients from follow up analysis, a 
success rate of 12/14 cases (86%) in treating preneoplasia was achieved. 
Conclusion: AIC of tracheobronchial secretions as well as AF are 
sensitive tools for the detection and localization of centrally located ELC 
lesions in a high-risk population. The complementary effect between both 
methods was represented as a 100% detection rate of all diagnosed 
preneoplasias.  
Recommendations: Patients with positive AIC or AF bronchoscopy 
without histopathological or cytological evidence of preneoplasia should 
be followed up carefully as they may harbor a yet morphologically 
undetectable ELC. The cut off points of 2cDI in the evaluation of 
preneoplasia may have to be redefined and differentiated from that for 
invasive cancer. The previously mentioned scheme for preneoplasia 
management proved a success rate of 86% in its treatment. AIC of 
tracheobronchial secretions and WLB/AF proved to be useful, rapid, 
accurate and inexpensive methods that should be highly effective, in 
combination with other complementary methods, as a screening tool in 
asymptomatic, high-risk patients. 
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